NextFin News - The pharmaceutical industry is converging on a genetic variant of cholesterol as the next multi-billion-dollar frontier in cardiovascular medicine, with Novartis, Amgen, and Eli Lilly racing to validate drugs targeting lipoprotein(a), or Lp(a). Unlike the common LDL cholesterol that can be managed through diet and statins, Lp(a) levels are almost entirely determined by genetics, leaving an estimated one in five people globally with high levels and no approved pharmacological treatment to lower them.
The stakes for this "hidden" cholesterol reached a critical juncture on Monday as Novartis prepared for the imminent readout of its Phase 3 HORIZON trial for pelacarsen. This study is the first large-scale clinical test of whether aggressively lowering Lp(a) actually translates into fewer heart attacks and strokes. According to CNBC, the results from Novartis, expected within the first half of 2026, will serve as a bellwether for a pipeline of similar therapies currently in development by Amgen and Eli Lilly.
Lp(a) has long been recognized by researchers as a "double threat" because it promotes both the buildup of fatty plaques in arteries and the formation of blood clots. Despite its discovery in 1963, it remained a secondary concern for decades while the industry focused on LDL. However, the success of the GLP-1 weight-loss class has reignited interest in chronic metabolic and heart conditions, leading drugmakers to hunt for the next major unmet need in cardiology. Dr. Steve Nissen, chief academic officer at the Cleveland Clinic and principal investigator for the Novartis trial, noted that while genetic evidence is strong, the industry must remain cautious. Nissen, who has overseen numerous landmark cardiovascular trials, pointed out that previous attempts to improve heart health by raising "good" HDL cholesterol failed despite promising early data.
The commercial opportunity is vast but carries significant clinical risk. Amgen is currently recruiting for its own Phase 3 OCEAN(a)-Outcomes trial for olpasiran, with a primary completion date estimated for March 2028. Eli Lilly is also advancing muvalaplin, an oral alternative to the injectable treatments being developed by its peers. While the science suggests that lowering Lp(a) by 80% or more—as seen in Phase 2 trials—should reduce cardiovascular risk, the "Lp(a) hypothesis" remains unproven until the Novartis data is unblinded.
Skeptics in the medical community argue that the cost of these new therapies could be a barrier to widespread adoption, especially if the absolute risk reduction is modest. Furthermore, because Lp(a) testing is not yet a standard part of routine physical exams, a massive diagnostic effort would be required to identify the millions of asymptomatic patients who might benefit. For now, the cardiology world is holding its breath for the Novartis readout, which will determine if Lp(a) becomes the next blockbuster category or another expensive footnote in the history of heart disease research.
Explore more exclusive insights at nextfin.ai.
